The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial
Open accessAbstract
Importance: Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients. Objective: To demonstrate that galcanezumab is superior to placebo in the prevention of episodic migraine with or without aura. Design, Setting, and Participants: The EVOLVE-1 (Evaluation of LY2951742 in the Prevention of Episodic Migraine 1) trial was a double-blind, randomized, placebo-controlled (January 11, 2016, to March 22, 2017) trial comparing galcanezumab (120 mg and 240 mg) vs placebo. Patients received treatments once monthly for 6 months (subcutaneous injection via prefilled syringe) and were followed up for 5 months after their last injection. It was a multicenter, clinic-based study involving 90 sites in North America. Participants in the study were adults (aged 18 to 65 years) with at least a 1-year history of migraine, 4 to 14 migraine headache days per month and a mean of at least 2 migraine attacks per month within the past 3 months, and were diagnosed prior to age 50 years. During the study, no other preventive medications were allowed. A total of 1671 patients were assessed; 809 did not meet study entry or baseline criteria, and 858 were included in the intent-to-treat population. Interventions: Patients were randomized (2:1:1) to monthly placebo, galcanezumab, 120 mg, and galcanezumab, 240 mg. Main Outcomes and Measures: The primary outcome was overall mean change from baseline in the number of monthly migraine headache days during the treatment period. Secondary measures included at least 50%, at least 75%, and 100% reduction in monthly migraine headache days, migraine headache days with acute medication use, and scores from the Migraine-Specific Quality of Life questionnaire, Patient Global Impression of Severity, and Migraine Disability Assessment. Treatment-emergent adverse events and serious adverse events were reported. Results: Of the 1671 patients assessed, 858 (mean age, 40.7 years; 718 women [83.7%]) met study entry criteria and received at least 1 dose of investigational product. The primary objective was met for both galcanezumab doses; treatment with galcanezumab significantly reduced monthly migraine headache days (both P < .001) by 4.7 days (120 mg) and 4.6 days (240 mg) compared with placebo (2.8 days). All key secondary objectives were also significant after multiplicity adjustment. There were no meaningful differences between 120-mg and 240-mg doses of galcanezumab on measures of efficacy. Completion rate during treatment was high (81.9%; n = 718), and the incidence of discontinuation owing to adverse events was less than 5% across all treatment groups. Conclusions and Relevance: Galcanezumab 120-mg and 240-mg monthly injections provided clinical benefits and improved functioning. The incidence rate of adverse events was low, demonstrating the favorable tolerability profile of galcanezumab. Trial Registration: ClinicalTrials.gov Identifier: NCT02614183.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Feigin, V. L., Abajobir, A. A., Abate, K. H., Abd-Allah, F., Abdulle, A. M., Abera, S. F., Abyu, G. Y., Ahmed, M. B., Aichour, A. N., Aichour, I., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30299-5 · Cited by 2,275
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,597
Goadsby, P. J., & Edvinsson, L. (1993) · Annals of Neurology · doi:10.1002/ana.410330109 · Cited by 1,158
Cgrp May Play A Causative Role in Migraine
Lassen, L., Haderslev, P., Jacobsen, V., Iversen, H., Sperling, B., & Olesen, J. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00310.x · Cited by 1,027
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
Self-citationGuidelines for Controlled Trials of Drugs in Migraine: Second Edition
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen, P., Block, G., Dahlöf, C., Diener, H.-C., Ferrari, M., Goadsby, P., Guidetti, V, Jones, B., Lipton, R., et al. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00117.x · Cited by 698
CGRP and its receptors provide new insights into migraine pathophysiology
Ho, T. W., Edvinsson, L., & Goadsby, P. J. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.127 · Cited by 523
(2006) · Annals of Neurology · doi:10.1002/(issn)1531-8249 · Cited by 513
Diamond, S., Bigal, M. E., Silberstein, S., Loder, E., Reed, M., & Lipton, R. B. (2007) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00631.x · Cited by 413
Blumenfeld, A. M., Bloudek, L. M., Becker, W. J., Buse, D. C., Varon, S. F., Maglinte, G. A., Wilcox, T. K., Kawata, A. K., & Lipton, R. B. (2013) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12055 · Cited by 380
Dodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368
Self-citationLipton, R. B., Stewart, W. F., Sawyer, J., & Edmeads, J. G. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2001.01156.x · Cited by 338
Juhasz, G., Zsombok, T., Modos, E. A., Olajos, S., Jakab, B., Nemeth, J., Szolcsanyi, J., Vitrai, J., & Bagdy, G. (2003) · Pain · doi:10.1016/j.pain.2003.09.008 · Cited by 270
Villalón, C. M., & Olesen, J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.09.003 · Cited by 209
Lipton, R. B., Manack Adams, A., Buse, D. C., Fanning, K. M., & Reed, M. L. (2016) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12878 · Cited by 191
Skljarevski, V., Oakes, T. M., Zhang, Q., Ferguson, M. B., Martinez, J., Camporeale, A., Johnson, K. W., Shan, Q., Carter, J., Schacht, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3859 · Cited by 172
Self-citationRendas‐Baum, R., Bloudek, L. M., Maglinte, G. A., & Varon, S. F. (2012) · Quality of Life Research · doi:10.1007/s11136-012-0230-7 · Cited by 128
Adherence with Migraine Prophylaxis in Clinical Practice
Berger, A., Bloudek, L. M., Varon, S. F., & Oster, G. (2012) · Pain Practice · doi:10.1111/j.1533-2500.2012.00530.x · Cited by 118
Cole, J. C., Lin, P. L., & Rupnow, M. F. T. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9217-1 · Cited by 107
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Diener, H., Lipton, R. B., Aurora, S. K., Nolan, M. E., & Silberstein, S. D. (2014) · Journal of Pain · doi:10.1016/j.jpain.2014.11.004 · Cited by 66
Self-citationGoadsby, P. J. (2016) · Brain · doi:10.1093/brain/aww236 · Cited by 46
Preventive Pharmacotherapy in Migraine
Rizzoli, P. B. (2013) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12273 · Cited by 41
Tolerance and Loss of Beneficial Effect During Migraine Prophylaxis: Clinical Considerations
Loder, E., & Rizzoli, P. B. (2011) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2011.01986.x · Cited by 36
Cited by
Ashina, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1915327 · Cited by 816
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Self-citationAmerican Headache Society (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13456 · Cited by 567
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Detke, H. C., Goadsby, P. J., Wang, S., Friedman, D. I., Selzler, K. J., & Aurora, S. K. (2018) · Neurology · doi:10.1212/wnl.0000000000006640 · Cited by 563
CGRP and the Trigeminal System in Migraine
Iyengar, S., Johnson, K. W., Ossipov, M. H., & Aurora, S. K. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13529 · Cited by 486
Metadata
- Authors
- Stauffer, V. L., Dodick, D. W., Zhang, Q., Carter, J. N., Ailani, J., & Conley, R. R.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-09-01
- Volume
- 75
- Issue
- 9
- Pages
- 1080
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2805937849
- Cited by
- 559
- References
- 28
- FWCI
- 44.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.